Skip to main content
. Author manuscript; available in PMC: 2016 Jun 8.
Published in final edited form as: Lancet Oncol. 2013 Mar 14;14(4):335–345. doi: 10.1016/S1470-2045(13)70055-X

Figure 1. Trial profile.

Figure 1

Because of the prevalence of end-stage cancer in this study, 27 deaths occurred; nine discontinued because of death, 16 died after study discontinuation, and two died after study completion. *Removals were done before unmasking of primary investigators. †Two participants in the enobosarm 3 mg group were included in the efficacy analysis but did not complete the trial (one withdrew consent, one because of non-compliance).